Pure Bioscience, Inc. (PURE) Stock Forecast Oct. 16, 2026
Analysis updated on Oct. 16, 2026 (UTC) · Alpha · vs marketSwitch to Total · OTC
Pure Bioscience, Inc. (PURE) stock forecast summary
Our AI ranks Pure Bioscience, Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
Pure Bioscience, Inc. is a small-cap company with a market capitalization of $10M. It ranks number 9 by market capitalization among the 9 Miscellaneous Chemical Products issuers in our coverage with a current forecast. Its Net Margin of -91.2% is the lowest of the 8 peers that report one. Its Gross Margin of 58.9% is the highest of the 9 peers that report one.
For PURE, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 5.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 3.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.8%, buy ≥ +0.2%, sell < -0.9%, strong sell < -1.2% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-16 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, PURE included.
Follow PURE freePURE price chart and AI forecast
How PURE ranks among 5172 stocks
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Pure Bioscience, Inc. (PURE) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Miscellaneous Chemical Products peers listed below that report each metric.
Valuation & Market
| Metric | PURE | Rank |
|---|---|---|
| Market Cap | $10M | 9/9 |
| EPS | $-0.02 | – |
| Revenue/Share | $0.02 | – |
Profitability & Margins
| Metric | PURE | Rank |
|---|---|---|
| ROA | -141.5% | 8/8 |
| ROIC | 91.4% | 1/9 |
| Gross Margin | 58.9% | 1/9 |
| Operating Margin | -79.2% | 8/9 |
| Net Margin | -91.2% | 8/8 |
| EBT Margin | -63.5% | 8/9 |
Financial Health
| Metric | PURE | Rank |
|---|---|---|
| Current Ratio | 0.42x | 9/9 |
| Quick Ratio | 0.36x | 9/9 |
| Interest Coverage | -5.1x | 6/8 |
| Working Capital | -$2M | 9/9 |
Cash Flow
| Metric | PURE | Rank |
|---|---|---|
| Operating Cash Flow | -$2M | 7/9 |
Operational Efficiency
| Metric | PURE | Rank |
|---|---|---|
| Asset Turnover | 1.55x | 1/7 |
| Receivables Turnover | 10.0x | 1/5 |
| Inventory Turnover | 4.3x | 6/9 |
| Fixed Assets Turnover | 268.8x | 1/7 |
| Days Sales Outstanding | 37 days | 5/5 |
| Days Inventory | 85 days | 4/9 |
| Payables Period | 263 days | 1/9 |
| Cash Conversion Cycle | -142 days | 5/5 |
Income Statement
| Metric | PURE | Rank |
|---|---|---|
| Total Revenue | $2M | 7/7 |
| Operating Income | -$2M | 6/9 |
| Net Income | -$2M | 5/8 |
| R&D Expense | $310K | 8/8 |
| SG&A Expense | $3M | 7/7 |
| Cost of Goods Sold | $1M | 9/9 |
Dividend & Shareholder Information
| Metric | PURE | Rank |
|---|---|---|
| Shares Outstanding | 130M | – |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $2M | |
| Cash & Short-term Investments | $980K | |
| Accounts Receivable | $240K | |
| Inventory | $230K | |
| Total Liabilities | $7M | |
| Short-term Debt | $3M |
PURE quarterly financials and insider trading
Pure Bioscience, Inc. (PURE) industry peers
Companies classified under the same SEC industry code as Pure Bioscience, Inc. (Miscellaneous Chemical Products): 9 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| PURE Pure Bioscience, Inc. | ▲ | $10M |
| ESI Element Solutions Inc | ▼ | $8.49B |
| CBT Cabot Corp | ▼ | $3.84B |
| WDFC Wd 40 Co | ▼ | $2.69B |
| FTK Flotek Industries Inc/Cn/ | ▲ | $871M |
| ASPI Asp Isotopes Inc. | ▼ | $328M |
| OEC Orion S.A. | ▶ | $302M |
| ARQ Arq, Inc. | ▲ | $78M |
| FSI Flexible Solutions International Inc | ▼ | $77M |
Where PURE sits on the market map
Pure Bioscience, Inc. (PURE) stock news
Loading...
Pure Bioscience, Inc. (PURE) stock forecast FAQ
What is the Pure Bioscience, Inc. (PURE) stock forecast?
Our AI ranks Pure Bioscience, Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
How accurate are Pure Bioscience, Inc. stock predictions?
For PURE, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 5.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 3.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Pure Bioscience, Inc. forecasts updated?
Pure Bioscience, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 16, 2026.
Which companies are Pure Bioscience, Inc.'s industry peers?
9 issuers in our coverage, PURE included, share the SEC industry code Miscellaneous Chemical Products. The largest are: Element Solutions Inc (ESI), Cabot Corp (CBT), Wd 40 Co (WDFC), Flotek Industries Inc/Cn/ (FTK), Asp Isotopes Inc. (ASPI), Orion S.A. (OEC).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.